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Abstract: The prognostic impact of the combination of the modified Glasgow prognostic score (mGPS)
and C-reactive protein/albumin ratio (CAR) in colorectal cancer (CRC) is unclear. We aimed to
investigate the clinical usefulness of this combination as a predictor of survival in CRC patients. We
retrospectively evaluated 769 CRC patients who had undergone surgery between January 2006 and
March 2014. The CAR and mGPS within 1 month postoperation were examined. The integrated area
under the curve (iAUC) was compared among mGPS, CAR, and the combined classification (CC).
The optimal CAR cut-off for discriminating overall survival was 0.14. Based on this cut-off, the mGPS
0 group was divided into the mGPS 0 with low CAR and the mGPS 0 with high CAR groups, whereas
all mGPS 1 and 2 patients were classified into the high CAR group. CC was an independent prognostic
factor, and its iAUC value (0.587, 95% CI 0.553–0.624) was superior to those of the mGPS (0.544,
95% CI 0.516–0.576) (bootstrap iAUC mean difference = 0.043; 95% CI = 0.015–0.072) and CAR (0.578,
95% CI 0.545–0.613) (bootstrap iAUC mean difference = 0.009; 95% CI = 0.002–0.017), respectively.
In conclusion, the combination of mGPS and CAR has a synergistic effect and has a higher prognostic
accuracy than mGPS or CAR alone in patients with CRC.
Keywords: modified glasgow prognostic score; C-reactive protein/albumin ratio; colorectal cancer;
survival; integrated area under the curve
1. Introduction
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide, accounting for
11% of all cancer diagnoses [1]. Approximately 1.8 million new cases of CRC were diagnosed in 2018,
and CRC is the most commonly diagnosed cancer among men in 10 of the 191 countries worldwide [1].
CRC also ranks third in terms of the estimated crude and age-standardized cancer mortality rates in
South Korea [2].
The American Joint Committee on Cancer (AJCC) staging system has been used as the standard
for decision-making for treatment, and the AJCC stage has been known as an independent factor for
distinguishing patients based on predicted survival outcomes [3]. However, there is a limitation that the
AJCC stage does not sufficiently reflect the patient’s prognosis [4–6]. Thus, many investigators continue
to attempt to predict prognosis using molecular or genomic data [7–9]. However, such methods are
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not cost-effective, and thus, routinely available prognosticators that can help clinical decision-making
need to be identified.
Systemic inflammation has been known as an important predictor of survival in patients with
CRC [10]. The modified Glasgow prognostic score (mGPS) is one of the most widely validated
prognostic tools, with numerous studies reporting that a high mGPS is associated with adverse patient
outcomes in various cancers, including CRC [11,12]. The C-reactive protein (CRP)/albumin ratio (CAR)
was recently introduced as an alternative prognostic marker in patients with CRC [13]. In this context,
a recent study simultaneously investigated the prognostic values of mGPS and CAR in the same cohort
and identified both as independent prognostic factors [14].
However, despite being derived from the same criteria involving circulating CRP and albumin
levels, the mGPS and CAR may have different clinical implications. Ishizuka et al. reported that
CAR can be used to further classify CRC patients with an mGPS of 0 and 1 into two separate groups,
with these groups showing different survival outcomes. This suggests the possibility of CAR and
mGPS being complementary [13]. However, the clinical significance of the combination of these two
indicators is yet to be clarified, and it remains unclear whether their combination has higher accuracy
for stratifying the prognosis of patients with CRC.
Thus, this study aimed to investigate the clinical usefulness of the combination of CAR and mGPS
in comparison to that of mGPS or CAR alone for predicting the survival of patients with CRC.
2. Materials and Methods
2.1. Study Design and Patient
This retrospective, single-center study was approved by the Institutional Review Board of
our hospital (approval number: 3-2020-0144; 27 May 2020). The need for informed consent was
waived owing to the retrospective nature of the study. The subjects were patients with stage
I–III CRC who underwent curative resection at Gangnam Severance Hospital, Yonsei University
College of Medicine between January 2006 and March 2014. The inclusion criteria were as follows:
(1) pathologically confirmed CRC, (2) surgery with curative intent, and (3) measurement of CRP
and albumin levels within 31 days of surgery. The exclusion criteria were as follows: (1) emergency
operations, (2) history of familial adenomatous polyposis or hereditary nonpolyposis colorectal
cancer, (3) history of inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease,
(4) preoperative radiotherapy or chemoradiotherapy, and (5) double primary cancers (Figure 1).
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2.2. Follow-Up Protocol
Follow-up involved outpatient clinic visits every 3 months for 3 years and every 6 months
thereafter until 5 years. The serum carcinoembryonic antigen (CEA) level was routinely measured
at each follow-up visit. Abdominopelvic computed tomography (CT) was performed at an average
interval of 6 months. Colonoscopy, chest CT, or 18F-fluorodeoxyglucose positron-emission tomography
was performed as indicated according to the surgeon’s discretion. Patient follow-up lasted until
the cut-off date (October 2019) or death. The patients were followed up for a median of 91 months
(interquartile range, 67–115 months).
2.3. mGPS, CAR, and the Combination of These Two Parameters
The mGPS was determined as follows: mGPS 0 = CRP ≤ 10 mg/L, mGPS 1 = CRP >10 mg/L and
albumin ≥3.5 g/dL, and mGPS 2 = CRP >10 mg/L and albumin <3.5 g/dL. Meanwhile, the CAR was
calculated as follows: CAR = serum CRP level (mg/dL)/serum albumin level (g/dL) [15]. The optimal
cut-off value for the CAR was defined as the reference value that could produce the largest χ2 in the
Mantel–Cox test [16]. Each mGPS was allocated to one of the two groups based on this cut-off value of
the CAR. This new combination was denoted as the combined classification (CC) throughout the rest
of this study.
2.4. Statistical Analysis
All statistical analyses were performed using R v. 3.6.3 (R-project, Institute for Statistics and
Mathematics, Vienna, Austria). Differences in the distribution of categorical variables were compared
using the chi-square test, while those in the distribution of continuous variables were analyzed using
the Kruskal–Wallis test. Overall survival (OS) was estimated using the Kaplan–Meier method and
compared using the log-rank test. The Cox proportional hazard model was used to estimate HRs and
95% CIs for factors associated with OS. Significant factors (p < 0.1) in the univariate Cox regression
analysis were entered into multivariate analysis models.
The prognostic capabilities of the mGPS, CAR, and CC were compared by generating
time-dependent ROC curves and by calculating the estimated AUC. Time-dependent ROC curve
analysis is an extension of ROC curve analysis and assesses the discriminatory power of continuous
markers for time-dependent disease outcomes. In addition to visually comparing the ROC curves,
the AUC can be calculated. The integrated AUC (iAUC) is a weighted average of the AUC across a
specific period. This is a way of measuring predictive ability of the model during a period of follow-up.
A higher iAUC indicates a better prognostic performance. The bootstrapping method was used to
calculate the differences and 95% confidence interval [17]. Harrell’s concordance index (C-index)
indicated the model’s ability to accurately predict specific outcomes and discrimination was evaluated
using C-index [18]. The value of C-index ranged from 1 to 0.5, which represents a perfect prediction
and a random chance to correctly predict the outcomes, respectively. The performance was compared
by measuring the discrimination ability using bootstraps with 1000 resamples. A two-sided p < 0.05
was considered statistically significant.
3. Results
3.1. Patient Characteristics
Comparison of Clinicopathologic Factors According to mGPS
A total of 769 patients who underwent potentially curative resection for CRC were included in
the analysis (Table 1). The most common mGPS score was 0 (n = 609, 79.2%), followed by 1 (n = 122,
15.8%), and 2 (n = 38, 4.9%). Age, American Society of Anesthesiologist (ASA) grade, CEA levels,
tumor location, tumor size, histologic grade, complications, number of retrieved lymph nodes (LNs),
and AJCC stage were independently associated with the mGPS. Meanwhile, sex, body mass index
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(BMI), lymphovascular invasion (LVI), and chemotherapy were not independently associated with the
mGPS. A higher mGPS was more likely to be associated with a higher CAR than a low mGPS.













Female 229 (37.6) 38 (31.1) 16 (42.1)
0.316Male 380 (62.4) 84 (68.9) 22 (57.9)
Age (years) <70 428 (70.3) 61 (50) 18 (47.4) <0.001
≥70 181 (29.7) 61 (50) 20 (52.6)
ASA grade
1 and 2 526 (86.4) 97 (79.5) 27 (71.1)
0.0413 and 4 54 (8.9) 18 (14.8) 8 (21.1)
No data 29 (4.8) 7 (5.7) 3 (7.9)
BMI (kg/m2)
<25 414 (68) 86 (70.5) 28 (73.7)
0.784≥25 184 (30.2) 35 (28.7) 10 (26.3)
No data 11 (1.8) 1 (0.8) 0
CEA (ng/mL)
<5 422 (69.3) 86 (70.5) 18 (47.4)
0.019≥5 165 (27.1) 35 (28.7) 19 (50)
No data 22 (3.6) 1 (0.8) 1 (2.6)
Tumor location
Colon 393 (64.5) 97 (79.5) 35 (92.1)
<0.001Rectum 216 (35.5) 25 (20.5) 3 (7.9)
Tumor size (cm) <7 551 (90.5) 89 (73) 20 (52.6) <0.001
≥7 58 (9.5) 33 (27) 18 (47.4)
Histologic grade
G1 and G2 568 (93.3) 108 (88.5) 29 (76.3)
0.003G3 21 (3.4) 6 (4.9) 5 (13.2)
Others 20 (3.3) 8 (6.6) 4 (10.5)
LVI
Absent 453 (74.4) 92 (75.4) 26 (68.4)
0.422Present 133 (21.8) 29 (23.8) 11 (28.9)
No data 23 (3.8) 1 (0.8) 1 (2.6)
Complications 128 (21) 38 (31.1) 12 (31.6) 0.024
Number of retrieved LNs Mean (SD) 22.4 (14.6) 26 (15.4) 26.8 (14.1) 0.005
AJCC stage
I 157 (25.8) 20 (16.4) 2 (5.3)
0.001II 184 (30.2) 47 (38.5) 21 (55.3)
III 268 (44) 55 (45.1) 15 (39.5)
Chemotherapy 370 (60.8) 74 (60.7) 24 (63.2) 0.956
CAR Mean (SD) 0.1 (0.1) 0.8 (0.8) 1.7 (1.6) <0.001
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CEA, carcinoembryonic antigen;
LVI, lymphovascular invasion; LN, lymph node; CAR, C-reactive protein/albumin ratio; mGPS, modified Glasgow
prognostic score.
3.2. Cut-off Value of CAR
The cut-off value of the CAR that produced the largest χ2 in the Mantel–Cox test was 0.14
(Figure 2).
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Figure 2. Determining the cut-off value of the CAR using the X-tile program. The variable color points
in the X-tile plots represent associated strength at each split from low (dark, black) to high (bright,
red, or green). Red indicates an inverse association between the expression levels and survival of the
variables, while green indicates a direct association. We defined optimal cut-off value as the value that
produced the largest χ2 in the Mantel–Cox test, which was set as 0.14.
3.3. Combined Classification and Survival
Based on this value, the patients were divided into two subgroups in the succeeding survival
analysis as follows: CAR-low (n = 541, 70.3%) and CAR-high (n = 228, 29.6%). In the Kaplan–Meier
survival analysis, both the mGPS and CAR were significantly associated with OS. For the combined
classification (CC) (i.e., combination of mGPS and CAR), all patients were initially re-classified into six
groups (mGPS: 0, 1, 2; and CAR: low and high). However, no patient satisfied the “mGPS 1 with low
CAR” and “mGPS 2 with low CAR” classifications. Therefore, only four CC groups were included in
the survival analysis, and the Kaplan–Meier survival curves showed significant differences among the
four groups (p < 0.0001) (Figure 3).
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. . i ri te l sis
I t i ri t l sis, age (p < 0. 01), BMI (p = 0.018), CEA level (p < 0.001), tumor size
(p = 0.045), LVI (absent vs. present, p < 0.001), number of retrieved LNs (p = 0.017), and AJCC stage
(I vs. II, p = 0.006; I vs. III, p < 0.001) were significantly associated with OS (Table 2). The PS r
s si ific tl rs t t 0 group (hazard ratio ( R) = . , c fi c
i t r al (CI) = 1.38–3.90, p = 0. 01), whereas there was no significant differenc in OS between the mGPS
1 and mGPS 0 groups (HR = 1.35, 95% CI = 0.92–1.96, p = 0.118). The CAR-high group also tended
to show a po rer survival rate than the CAR-low group (HR = 1.97, 95% CI = 1.47–2.64, p < 0.001)
(Table 2). Among the four CC groups, Group 1 (mGPS 0 and low CAR) showed a significantly better
OS than the other three groups (vs. Group 2 (mGPS 0 and high CAR): H = 2.43, 95% CI = 1.60–3.69,
p < 0.001; vs. Group 3 (mGPS 1 and high CAR): HR = 1.54, 95% CI = 1.04–2.27, p = 0.028; vs. Group 4
(mGPS 2 and high CAR): HR = 2.65; 95% CI = 1.56–4.49, p < 0.001).
a le 2. i i t l sis f t fact rs ass ciate ith overall survival.
Variables HR (95% CI) p
Sex
Female 1
Male 1.54 (1.11–2.13) 0.008
Age (years) <70 1
≥70 3.51 (2.61–4.73) <0.001
AS grade
1 and 2 1
3 and 4 1.29 (0.81–2.07) 0.279
No data 0.91 (0.47–1.74) 0.778
BMI (kg/m2)
<25 1
≥25 0.65 (0.46–0.93) 0.018
No data 1.14 (0.42–3.09) 0.793
CEA (ng/mL)
<5 1
≥5 1.90 (1.40–2.56) <0.001
No data 1.25 (0.51–3.08) 0.622
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Table 2. Cont.
Variables HR (95% CI) p
Tumor location
Colon 1
Rectum 0.91 (0.66–1.25) 0.58
Tumor size (cm) <7 1
≥7 1.46 (1.0–2.12) 0.045
Complications No 1
Yes 1.40 (1.02–1.94) 0.037
Histologic grade
G1 and G2 1
G3 1.36 (0.69–2.67) 0.364
Others 1.58 (0.86–2.92) 0.139
LVI
Absent 1
Present 1.71 (1.24–2.36) <0.001
No data 0.85 (0.34–2.09) 0.732
Number of retrieved LNs
<12 1
≥12 0.65 (0.46–0.92) 0.017
AJCC stage
I 1
II 2.04 (1.22–3.40) 0.006
III 3.18 (1.97–5.13) <0.001
Chemotherapy No 1
Yes 0.78 (0.58–1.05) 0.109
mGPS
0 1
1 1.35 (0.92–1.96) 0.118
2 2.32 (1.38–3.90) 0.001
CAR
Low 1
High 1.97 (1.47–2.64) <0.001
Combined classification
Group 1 1
Group 2 2.43 (1.60–3.69) <0.001
Group 3 1.54 (1.04–2.27) 0.028
Group 4 2.65 (1.56–4.49) <0.001
Abbreviations: HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; BMI, body
mass index; CEA, carcinoembryonic antigen; LVI, lymphovascular invasion; LN, lymph node; mGPS, modified
Glasgow prognostic score; CAR, C-reactive protein/albumin ratio.
3.5. Multivariate Analysis
First, we evaluated prognostic significance among mGPS, CAR, and CC. Using multivariate
analysis and including only three parameters, CC remained the only significant factor (data
not shown). Thus, CC was included in the final multivariate analysis adjusting with
clinicopathological variables. In the multivariate survival analysis, CC was associated with OS,
independent of sex, age, BMI, CEA, complications, number of retrieved LNs, and AJCC stage (Group 1
vs. Group 4, HR = 1.90, 95% CI = 1.09–3.30, p = 0.022) (Table 3).
Table 3. Multivariate analysis of the factors associated with overall survival.
Variables HR (95% CI) p
Sex
Female 1
Male 1.41 (1.01–1.97) 0.038
Age (years) <70 1
≥70 3.21 (2.35–4.38) <0.001
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Table 3. Cont.
Variables HR (95% CI) p
BMI (kg/m2)
<25 1
≥25 0.69 (0.49–0.99) 0.045
No data 1.07 (0.38–2.97) 0.886
CEA (ng/mL)
<5 1
≥5 1.43 (1.04–1.96) 0.024
No data 2.22 (0.88–5.57) 0.087
Complications No 1
Yes 1.36 (0.98–1.90) 0.063
Number of retrieved LNs
<12 1
≥12 0.54 (0.37–0.77) <0.001
AJCC stage
I 1
II 1.93 (1.12–3.31) 0.017
III 3.41 (2.04–5.69) <0.001
Combined classification
Group 1 1
Group 2 1.47 (0.95–2.29) 0.083
Group 3 1.14 (0.76–1.70) 0.504
Group 4 1.90 (1.09–3.30) 0.022
Abbreviations: HR, hazard ratio; CI, confidence interval; BMI, body mass index; CEA, carcinoembryonic antigen;
LN, lymph node.
3.6. Time Dependent ROC among mGPS, CAR, and CC
Time-dependent receiver operating characteristic (ROC) curve of mGPS, CAR, and CC at 5 year
revealed Area Under the Curve (AUC) value as 0.553, 0.591, and 0.6 respectively (Figure 4).
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95% CI = 0.516–0.576) (bootstrap iAUC mean difference = 0.043, 95% CI = 0.015–0.072) and CAR (0.578, 
95% CI = 0.545–0.613) (bootstrap iAUC mean difference = 0.009, 95% CI = 0.002–0.017), respectively, 
throughout the observation period (Figure 5). The C-index of CC (0.587, 95% CI = 0.549–0.628) showed 
superior discriminatory power to that of the mGPS (0.546, 95% CI = 0.515–0.580) (bootstrap mean 
difference = 0.040; 95% CI = 0.013–0.071) and CAR (0.578, 95% CI = 0.542–0.617) (bootstrap mean 
difference = 0.008; 95% CI = 0.001–0.016), respectively. 
  
i r . Ti e- e e e t r i r r ti t i i , , .
3.7. Integrated AUC and C-Index Comparison among mGPS, CAR, and CC
The integrated AUC value (0.587, 95% CI = 0.553–0.624) was superior to those of the mGPS (0.544,
95% CI = 0.516–0.576) (bootstrap iAUC mean difference = 0.043, 95% CI = 0.015–0.072) and CAR (0.578,
95% CI = 0.545–0.613) (bootstrap iAUC mean difference = 0.009, 95% CI = 0.002–0.017), respectively,
throughout the observation period (Figure 5). The C-index of CC (0.587, 95% CI = 0.549–0.628) showed
superior discriminatory power to that of the mGPS (0.546, 95% CI = 0.515–0.580) (bootstrap mean
difference = 0.040; 95% CI = 0.013–0.071) and CAR (0.578, 95% CI = 0.542–0.617) (bootstrap mean
difference = 0.008; 95% CI = 0.001–0.016), respectively.
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cancers [23]. Inamoto et al. also reported that the combination of the GPS and neutrophil-to-lymphocyte
ratio (NLR) can be used to effectively stratify patient outcomes, with patients with an NLR of <2.05
and a GPS of 0 having a remarkably better prognosis [24].
The mGPS and CAR are easy to use in combination because they are both assessed using the
same laboratory variables. A previous study showed that patients with an mGPS of 0 and 1 could be
further classified into two different groups based on the cut-off value of the CAR [13], suggesting that
the mGPS and CAR act as complementary variables. However, the synergistic effect of combining
these two parameters has not been fully investigated. Our study demonstrated that combining these
two parameters could provide better predictive power throughout the time points, and CC can,
thus, be used as an effective inflammation-based prognostic marker instead of mGPS or CAR alone.
The mGPS 0 and low CAR group showed a better prognosis than the other groups. Such characteristics
may be an indication for selecting the 3-month FOLFOX chemotherapy regimen over the conventional
6-month treatment regimen in patients with stage III colon cancer or in patients with stage II colon
cancer who did not receive adjuvant chemotherapy. However, further prospective studies should be
performed to prove these hypotheses.
Although several studies have provided evidence supporting the prognostic value of the mGPS,
some studies have reported conflicting findings. Son et al. reported that the mGPS does not predict
OS (mGPS 2 vs. 0–1, HR = 2.217, 95% CI = 0.716–6.864, p = 0.167) [25]. Chan et al. also reported that
the mGPS is not a significant prognosticator in a multivariate analysis (p = 0.06) [26]. Many results
favoring the mGPS as a significant prognostic factor in patients with CRC have been derived from
studies using a similar cohort [15,27–30]. As most of these studies analyzed the mGPS as a continuous
value rather than a categorical value on multivariate analysis, the score showing statistical power
remains unclear [15,27–30]. In a recent systematic review, the majority (60%) of patients had an mGPS
of 0, with only 25% and 14.8% of patients having an mGPS of 1 and 2, respectively [11]. In contrast,
some studies evaluated a cohort in which more than 80% of the patients had an mGPS of 0, which is
associated with good prognosis. Factors including geography, ethnicity, and patient characteristics can
explain the diversity in the distribution of the mGPS in the study cohorts. Importantly, there may be
some heterogeneity in studies in which the majority of the patients have an mGPS of 0. Considering the
categorical classification used for the mGPS, this can be a confounding situation that can reduce the
discrimination capability of the mGPS [31]. Although the mechanism underlying the synergistic effect
of the combination of the mGPS and CAR remains unclear, our results indicate that patients with an
mGPS of 0 can be further classified into good prognosis and poor prognosis groups, which is consistent
with previous findings [13].
Our study has some limitations. Owing to the retrospective, single-center design of the study,
selection bias may be inevitable. Nevertheless, the cohort involved patients who received standardized
treatments based on consistent principles at a tertiary university hospital throughout the study
period. In a recent meta-analysis, the cut-off values for the CAR ranged from 0.028 to 0.65 [32]; thus,
the prognostic value of the CAR in patients with CRC cannot be compared definitely between studies.
Further, this study could not provide specific cut-off values for the CAR that could be appropriate for the
general population owing to differences in ethnic and patient characteristics. A clearer standard for the
cut-off value is needed to expand its clinical use. Another limitation is that this study included patients
who underwent blood tests within one month of surgery, regardless of the patients’ inflammatory status.
However, it was difficult to accurately exclude patients with inflammation due to causes other than
cancer at that point due to the retrospective study design. In addition, there may be some differences
in sampling time between patients, although most of the patients underwent blood test within two
weeks before surgery (median 6 days, interquartile range 3–11 days). It cannot be ruled out that the
different timing of blood tests will affect our findings, and future clinical trials should control this
factor in a well-designed manner. The ability to discriminate survival can be improved when our
combined classification is added to the AJCC stage, which is currently used as a standard for predicting
patient prognosis in patients. Nevertheless, the iAUC value of CC alone was analyzed to be about
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0.58, and considering the relatively low iAUC values even in CAR or mGPS, these indicators seems to
not be strong for predicting patient prognosis. Therefore, future work is needed to find more useful
predictive models using serum inflammatory markers in order to be used more meaningfully in the
management of CRC patients.
5. Conclusions
Our study showed that the combination of the mGPS and CAR had a synergistic effect, and thus,
had a better prognostic accuracy than the mGPS or CAR alone in patients with CRC. This combination
can be used for the risk stratification of patients with CRC in clinical trials to establish its usefulness in
routine clinical practice.
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